ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

1:00PM-3:00PM: Abstract Number: 2044

Abnormalities of Extracellular Matrix Modeling Gene Expression in Salivary Gland Epithelial Cells of Patients with Sjögren’s Syndrome

Sjögren's Syndrome – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 2118

Achieving Increasingly Stringent Clinical Disease Control Criteria Is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

Spondyloarthritis Including PsA – Treatment Poster III: PsA

1:00PM-3:00PM: Abstract Number: 2088

Achieving Systemic Lupus Erythematosus Disease Control or Low Lupus Disease Activity State Is Associated with Lower Rates of Organ Damage: Results from the Hopkins Lupus Cohort

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 1914

Acoustic Classification of Early and Advanced Osteoarthritis of the Knee in Clinical Settings

Osteoarthritis – Clinical Poster

1:00PM-3:00PM: Abstract Number: 1817

Acute Coronary Syndrome in Calcium Pyrophosphate Deposition Disease Patients: A Cross-sectional Study from the National Inpatient Sample

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1937

Adult Rheumatologists’ Knowledge, Comfort Level, and Perceived Barriers in Supporting Newly Transitioned Youth with Chronic Rheumatic Diseases in Canada

Pediatric Rheumatology – Clinical Poster III: Other

1:00PM-3:00PM: Abstract Number: 1756

Adverse Events in Patients with Inflammatory Joint Diseases: Results from the EULAR Coronavirus Vaccine (COVAX) Physician-reported Registry

Epidemiology and Public Health Poster III

1:00PM-3:00PM: Abstract Number: 2046

Agreement Between Labial Biopsy and the OMERACT Grey-scale Ultrasound Scoring System for Salivary Glands in a Single-center Cohort of Patients with Suspected Sjögren’s Syndrome

Sjögren's Syndrome – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1896

Alkylresorcinol, a Biomarker for Whole Grain Intake, and Its Association with Osteoarthritis: The MOST Study

Osteoarthritis – Clinical Poster

1:00PM-3:00PM: Abstract Number: 2068

All-Cause Mortality in a Systemic Lupus Erythematosus Cohort

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 2161

Alterations of Nutritional Status of Scleroderma Patients and Associations with Disease-specific Features

Systemic Sclerosis and Related Disorders – Clinical Poster III

1:00PM-3:00PM: Abstract Number: 2154

An Exploratory Phosphoproteomic and Immunohistochemical Analysis of Receptor Tyrosine Kinases and Downstream Signaling Pathways in Systemic Sclerosis Skin

Systemic Sclerosis and Related Disorders – Clinical Poster III

1:00PM-3:00PM: Abstract Number: 2098

Analysis of Cutaneous Lupus Hospitalizations: A United States National Population-based Study

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 1926

Analysis of New Patient Referrals to a Large Pediatric Rheumatology Clinic

Pediatric Rheumatology – Clinical Poster III: Other

1:00PM-3:00PM: Abstract Number: 2148

Analysis of Serum Proteomics Data Identifies Beta-Defensin 2 as a Predictive Biomarker of Clinical Response to IL-17 Blockade in Psoriatic Arthritis

Spondyloarthritis Including PsA – Treatment Poster III: PsA

«Previous Page
1
…
4
5
6
7
8
…
45
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].